Tardive Dyskinesia Therapeutics Market Report 2026

Tardive Dyskinesia Therapeutics Market Overview

• Tardive Dyskinesia Therapeutics market size has reached to $3.12 billion in 2025 • Expected to grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Mental Health Disorders Driving The Growth Of The Market Due To Increasing Use Of Long-Term Antipsychotics • Market Trend: Advancements In Once-Daily Treatment Options Enhancing Consistent Drug Delivery And Patient Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tardive Dyskinesia Therapeutics Market?

Tardive dyskinesia therapeutics involve treatments designed to reduce or manage the uncontrollable, repetitive movements associated with this neurological disorder. These therapies are developed to target the underlying neurological imbalances often associated with prolonged use of certain medications. The goal is to improve patient quality of life by reducing the severity and frequency of motor disturbances, restoring functional abilities, and minimizing long-term complications. The main drugs of tardive dyskinesia therapeutics are deutetrabenazine, valbenazine, and others. Deutetrabenazine is a vesicular monoamine transporter type 2 (VMAT2) inhibitor used as a medication to manage involuntary movements associated with tardive dyskinesia. It offers various product types including solid dosage forms, tablets, capsules, liquid dosage form, and injection and is applied for antipsychotic-induced tardive dyskinesia, other drug-induced tardive dyskinesia, and idiopathic tardive dyskinesia. It is used by several end-users such as hospitals, clinics, specialty treatment centers, and homecare settings.

What Is The Tardive Dyskinesia Therapeutics Market Growth Forecast?

The tardive dyskinesia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to development of novel therapeutics for tardive dyskinesia, increased r&d investment in neurological disorders, rising preference for homecare settings, expansion of specialty treatment centers, enhanced patient monitoring and digital therapeutics. Major trends in the forecast period include rising adoption of deutetrabenazine and valbenazine, increased focus on personalized neurological therapy, expansion of homecare and remote treatment options, growing awareness about drug-induced tardive dyskinesia, emphasis on safety and compliance in long-term treatment.

Global Tardive Dyskinesia Therapeutics Market Segmentation

1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs 2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form 3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia 4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings Subsegments: 1) By Deutetrabenazine: Dosage Forms, Line Of Therapy, Distribution Channel 2) By Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel 3) By Other Drugs: Drug Class Or Type, Dosage Forms, Treatment Duration

What Is The Driver Of The Tardive Dyskinesia Therapeutics Market?

The increasing prevalence of mental health disorders is expected to propel the growth of the tardive dyskinesia therapeutics market going forward. Mental health disorders are conditions that affect a person’s thoughts, emotions, behavior, or functioning, often causing significant distress or difficulty in daily life. Mental health disorders are rising due to increasing social isolation, as the shift toward digital communication and fast-paced lifestyles has reduced meaningful in-person connections, resulting to greater feelings of loneliness and emotional strain. Tardive dyskinesia therapeutics support mental disorder patients by managing involuntary movement symptoms caused by long-term antipsychotic use, thereby improving treatment adherence and overall quality of life. For instance, in 2024, according to the National Alliance On Mental Illness, a US-based organization, among people in the U.S. aged 18-44, psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations each year. Therefore, the increasing prevalence of mental health disorders drives the tardive dyskinesia therapeutics industry.

Key Players In The Global Tardive Dyskinesia Therapeutics Market

Major companies operating in the tardive dyskinesia therapeutics market are Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd.

Global Tardive Dyskinesia Therapeutics Market Trends and Insights

Major companies operating in the tardive dyskinesia therapeutics market are focusing on developing advanced products, such as once-daily treatment options, to help maintain more consistent drug levels in the body. Once-daily treatment options refer to medications or therapies that are designed to be taken just once per day, simplifying dosing schedules and improving patient adherence. For instance, in May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for AUSTEDO XR tablets for treating adults with tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. The recent approval of AUSTEDO XR offers patients proven effectiveness in managing involuntary movements with the added convenience of a once-daily, single-pill dosage. This new formulation delivers clinically therapeutic doses confirmed by pivotal clinical trials. Additionally, it is now available in four different tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.

What Are Latest Mergers And Acquisitions In The Tardive Dyskinesia Therapeutics Market?

In February 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, partnered with Jiangsu Nhwa Pharmaceutical Co. Ltd. in order to promote and distribute Teva's AUSTEDO. The collaboration aims to expand patient access to Teva’s AUSTEDO by utilizing Nhwa’s strong presence in China’s neuropsychiatric health market. AUSTEDO is recognized as the first VMAT2 inhibitor approved by the U.S. FDA for treating tardive dyskinesia and chorea linked to Huntington’s disease in adults. Jiangsu Nhwa Pharmaceutical Co. Ltd. is a China-based pharmaceutical company.

Regional Insights

North America was the largest region in the tardive dyskinesia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tardive Dyskinesia Therapeutics Market?

The tardive dyskinesia therapeutics market consists of revenues earned by entities by providing services such as drug discovery, clinical trial management, formulation services, and pharmacovigilance. The market value includes the value of related goods sold by the service provider or included within the service offering. The tardive dyskinesia therapeutics market also includes sales of adjunctive medications, patient monitoring devices, drug delivery systems, and screening tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tardive Dyskinesia Therapeutics Market Report 2026?

The tardive dyskinesia therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.